CHIEF TECHNICAL OPS OFFICER
Neil Gregory Almstead, Ph.D., is the Chief Technical Operations Officer at PTC Therapeutics, Inc. (PTCT), a role he currently holds after over 20 years with the company since joining in 2000.[[1]](https://www.ptcbio.com/team/leadership/neil-almstead/)[[2]](https://insiderinsights.com/free/index.php?s=filer&o=-1&a=&q=Almstead+Neil+Gregory)[[4]](https://www.gurufocus.com/insider/64886/neil-gregory-almstead) He oversees research, manufacturing, and supply chain for small-molecule and gene-therapy programs, having progressed through executive positions including senior vice president of research, chemistry, manufacturing, and controls, and executive vice president of research, pharmaceutical operations, and technology.[[1]](https://www.ptcbio.com/team/leadership/neil-almstead/)
Prior to PTC, Almstead worked six years as a project manager at Procter & Gamble and has co-authored more than 75 publications and patents in genetic disorders, oncology, and inflammatory diseases.[[1]](https://www.ptcbio.com/team/leadership/neil-almstead/) He earned a Bachelor of Science from Clarkson University, a Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign, and completed postdoctoral research at the University of Basel.[[1]](https://www.ptcbio.com/team/leadership/neil-almstead/) As a corporate insider, he recently sold shares, including 1,026 shares on January 7, 2026, at $77.48, retaining ownership of approximately 116,077 shares valued at nearly $9 million, amid a pattern of 36 sales totaling over $12.7 million.[[3]](https://www.marketbeat.com/instant-alerts/neil-gregory-almstead-sells-1026-shares-of-ptc-therapeutics-nasdaqptct-stock-2026-01-08/)[[6]](https://www.quiverquant.com/news/Lobbying+Update:+$50,000+of+PTC+THERAPEUTICS+INC.+lobbying+was+just+disclosed)
View full insider profile →
